잠시만 기다려 주세요. 로딩중입니다.

새로운 혈당강하제 Glybenclamide(Daonil)의 치료효과

Clinical Studies on Glybenclamide(Daonil), a New Hypoglycemic Sulfonylurea in Korea

당뇨병 1972년 1권 1호 p.49 ~ 54
김응진, 김영건, 신순현, 이중근,
소속 상세정보
김응진 (  ) - 서울대학교 의과대학 내과학교실
김영건 (  ) - 서울대학교 의과대학 내과학교실
신순현 (  ) - 서울대학교 의과대학 내과학교실
이중근 (  ) - 서울대학교 의과대학 내과학교실

Abstract


The hypoglycemic effect of glybenclamide (Daonil), a new derivates of the hypoglycemic sulfonylureas, was studied on 41 diabetics registered at the Diabetic Clinics of Seoul National University Hospital. Observing the effect after administering for 13 months to these patients, the results were as follows:
1. Glybenclamide was given to 20 cases who had no experience of previous treatment and the result of excellent or good control was obtained in 18 cases (90%).
2. In 14 cases who had been treated with other sulfonylurea derivatives, 10 cases (71.4%) showed excellent or good control.
3. Glybenclamide treatment in 7 cases who had been treated with about 20 units of N.P.H. resulted in excellent or good control of diabetes in 5 cases (71.4%).
4. The influence of age, body weight, duration of disease and complication on the effect of glybenclamide was studied. According to the result, difference of age showed no remarkable influence on the effect of glybenclamide, but relatively better results were obtained in the group of obese patients. The shorter the duration of disease, the better the results. The patient with minor complication had same result as those who had no complications.
5. Glybenclamide, a sulfonylurea derivative with strong hypoglycemic effect, can be said to be one of the strongest oral hypoglycemic agents. Considering absence of any remarkable side effects or ´toxicity during the clinical studies and its relatively low dose necessary for diabetes control, glybenclamide is thought the most effective agent in long term therapy of diabetes.

키워드

원문 및 링크아웃 정보

등재저널 정보

KoreaMed
KAMS